Skip to main content
Equibles
TMDX logo

TMDX · TransMedics Group, Inc.

Track TMDX — free

Use TMDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TMDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$91.38 -0.62 (-0.67%) At close · Nov 13
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$3.17B
Shares
34.73M
Volume · Nov 13 840.86K Avg daily vol (3M) 894.64K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$91.38 Open$92.39 Day$91.17–94.28 52W close$62.04–150.42 Avg vol 30d1.1M Short int8.9M · 25.6% of shares · 10.2d Short vol65% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Next earnings call
Feb 23, 2027 Est · unconfirmed · in 14 wks
Q1 2026 earnings call transcript
call held May 5, 2026
Play latest call

Latest documents

2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue growth outpaced profit as expenses rose

TransMedics Group, Inc. generated total revenue of $566.9 million and net income of $39.1 million for the nine months ended September 30, 2026, while research, development, clinical trials and administrative expenses increased.

Revenue $203.01M ▲ 41.1% Net income $17.07M ▼ 29.8% Diluted EPS $0.46 ▼ 30.3%
Read from the MD&A section
3 source passages
We generated total revenue of $203.0 million and $566.9 million, and net income of $17.1 million and $39.1 million, for the three and nine months ended September 30, 2026, respectively. Total research, development and clinical trials expenses increased by $37.3 million from $48.4 million in the nine months ended September 30, 2025 to $85.7 million in the nine months ended September 30, 2026. Total selling, general and administrative expenses increased by $48.4 million from $133.7 million in the nine months ended September 30, 2025 to $182.1 million in the nine months ended September 30, 2026. Open the document at this passage
Nov 5
Current report 8-K
Strong revenue growth drives higher guidance

TransMedics Group, Inc. reported third-quarter revenue of $203.0 million, up 41%, net income of $17.1 million and raised full-year 2026 revenue guidance to $764-$774 million, including approximately $14 million from PAD Aviation.

Financial results
4 source passages
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2026. - Total revenue of $203.0 million, up 41%, including organic revenue growth* of 35% - Net income of $17.1 million or $0.46 per diluted share in the third quarter of 2026 - Raises full-year 2026 revenue guidance to between $764-$774 million, inclusive of approximately $14 million from PAD Aviation Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$727.65M
Trailing 12 months
Net income (TTM)
$144.45M
Trailing 12 months
Revenue growth YoY
+41.1%
Year over year
Operating margin
11.9%
Trailing 12 months
P / E (TTM)
25.0
Trailing earnings · reciprocal yield 4.0%
FCF yield
1.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$349.94M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.2%
Year over year · more shares
Price change (1Y)
-20.9%
Trailing year
Short interest
25.6%
Latest settlement · 10.2 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲49.8% $121.62M $6.86M '24 Q4* ▲48.2% $143.54M $25.68M '25 Q1 ▲37.7% $157.37M $34.91M '25 Q2 ▲32.2% $143.82M $24.32M '25 Q3 ▲32.2% $160.76M $105.38M '25 Q4* ▲21.2% $173.93M $7.32M '26 Q1 ▲20.7% $189.95M $14.68M '26 Q2 LATEST ▲41.1% $203.00M $17.07M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Mentioned in fund letters

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −0%
below
Price vs 50-day avg +14%
above
RSI (14) 66
neutral
MACD trend Positive
52-week position 33%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +29%
trailing
6-month return +30%
trailing
YTD return −25%
this year
Relative strength +29%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $80 › 200d $92 — 200d above 50d
Institutional flow Accumulating
336 of 385 funds reported for Sep 30 · net +1.9M sh shares · +41 new
Insider flow Distributing
Net -$276.4K over 90 days · 50% sells
Short interest Rising
25.56% of shares out · ▲ +1.2% MoM · 10.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
385 holders — mid 3-yr range
Squeeze score 83
high risk · 0–100
Fundamentals
Excellent
Revenue growth +37%
Y/Y
Gross margin 60%
expanding
EPS growth +382%
Y/Y
Free cash flow $133.6M
Balance sheet $23.5M
net debt
Quant / Vol
risk profile
Very High
Volatility 64%
annualized · 1-yr
Max drawdown −59%
past year
ATR 5.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 6
Latest guidance · from the 8-K filed Nov 5, 2026
FY 2026
FY 2026 Revenue (including PAD Aviation) $764M – $774M
prior FY $605.49M midpoint +27.0% Y/Y
Full-Year 2026
Expected PAD Aviation revenue $14M
Previous outlook earlier release · from the 8-K filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Full-year 2026 revenue guidance, excluding PAD Aviation · full year 2026 $737M – $757M
Guided vs delivered · last 6 settled
Full year 2025 revenue full year 2025
guided $595M – $605M
$605.49M Beat +0.9%
Full year 2024 revenue full year 2024
guided $425M – $445M
$441.54M In line
Full year 2023 revenue full year 2023
guided $222M – $230M
$241.62M Beat +6.9%
Net revenue full year 2022
guided $67M – $75M
$93.46M Beat +31.6%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 5 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−0% Neutral
Price vs 50-day avg
+14% Bullish
RSI (14)
66 Neutral
MACD trend
Positive Bullish
52-week position
33% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $80 › 200d $92 — 200d above 50d
Institutional flow Accumulating
336 of 385 funds reported for Sep 30 · net +1.9M sh shares · +41 new
Insider flow Distributing
Net -$276.4K over 90 days · 50% sells
Short interest Rising
25.56% of shares out · ▲ +1.2% MoM · 10.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
385 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $62 Now $91 · 33% Range high $150
vs 200-day avg 0% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted diluted net income per common share non-GAAP $0.75 Six Months Ended June 30, 2026 —
Adjusted diluted net income per share non-GAAP $0.44 Three Months Ended June 30, 2026 —
Adjusted income from operations non-GAAP 43.9M Six Months Ended June 30, 2026 —
Adjusted net income non-GAAP 27.13M Six Months Ended June 30, 2026 —
Adjusted operating margin % non-GAAP 12.1% Six Months Ended June 30, 2026 —
Gross margin from net product revenue 77% the three months ended June 30, 2026 filing —
Gross margin from service revenue 35% the three months ended June 30, 2026 filing —
Revenue from customers in the United States related to OCS transplant 183.6M the three months ended June 30, 2026 filing —
Revenue from customers outside the United States 5.2M the three months ended June 30, 2026 filing —
Total OCS transplant revenue 188.86M the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TMDX
TransMedics Group, Inc.
this stock
$3.17B -24.9% +37.1% — 25.6%
ABT
Abbott Laboratories
 $187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
 $131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
 $117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
 $64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
394
% held
115.1%
Reported
336 of 385
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
336
View
Short & Settlement
Short Interest Rising
Shares short
8.9M
Days to cover
10.2d
Change
+108.5K sh
View
Short Volume
Short vol %
65%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
4
Value
$316
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
43.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$276.4K
Buyers / Sellers
1 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$605.5M
Net income (FY)
$190.3M
EPS diluted
$4.87
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
20

TransMedics Group, Inc. generated total revenue of $566.9 million and net income of $39.1 million for the nine months ended September 30, 2026, while research, development, clinical trials and administrative expenses increased.

View
Proposed Sales
Value
$385.5K
Shares
4.1K
Filed
Nov 9, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 17, 2026
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
TransMedics Reports Inducement Gr…
Published
Oct 30, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
TMDX +3.6% +29.1% +29.7% +38.5% -24.9%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +1.0% +30.3% +29.2% +38.7% -35.5%
Key facts CIK 1756262 CUSIP 89377M109 13F (30d) 311 filings 274 filers Visit website Investor relations